Small Molecules
1 March 2016
Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis29 February 2016
Oncothyreon Announces First Patient Dosed in Randomized Phase 2 ONT-380 Combination Trial in Patients with HER2-Positive Breast Cancer29 February 2016
Clementia Announces Last Patient Enrolled in Phase 2 trial of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva29 February 2016
European Committee for Medicinal Products for Human Use recommends approval of Giotrif® (afatinib) for advanced squamous cell cancer of the lung29 February 2016
PharmaMar Initiates a Phase II Trial With Antitumour Drug PM184 in Advanced Breast Cancer29 February 2016
CHMP Issues Positive Opinion for LONSURF(R) (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer28 February 2016
FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)26 February 2016
European Medicines Agency Validates Gilead’s Marketing Application for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B26 February 2016
Servier Receives Positive CHMP Opinion for LONSURF® (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer26 February 2016
Allergan Announces FDA Approval of ACZONE® (dapsone) Gel, 7.5% for Treatment of Acne Vulgaris25 February 2016
Alkermes Announces Positive Topline Results From Clinical Study of Two-Month Dosing Option of ARISTADA® for Treatment of Schizophrenia25 February 2016
Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia25 February 2016
Gilead Announces Data From New Preclinical Study Evaluating an Investigational TLR7 Agonist in SIV-Infected Monkeys25 February 2016
Profound Preventative and Restorative Effects of ATB-346 in Mice with Genetic Predisposition to Intestinal Cancer24 February 2016
Gilead Announces Results From First Study to Evaluate Switching to F/TAF-Based Regimens from Truvada® (F/TDF)-Based Regimens24 February 2016
FDA Accepts and Grants Priority Review for AVYCAZ® (ceftazidime and avibactam) Supplemental New Drug Application (sNDA)24 February 2016
ViiV Healthcare Announces Phase II Study Results for First Two Drug, Long-acting Injectable Regimen for HIV-1 Treatment23 February 2016
Novan Announces First Patient Dosed in Phase 3 Program for SB20423 February 2016
Merck’s Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study23 February 2016
vTv Therapeutics Reports Preclinical and Clinical Results on its Diabetes Candidate TTP273News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports